Disease & disorder

adenocarcinoma

MONDO:0004970

A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.

Clinical trials66
Recruiting5
Drug concepts studied20
Synonyms6

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…

Clinical trials

40 shown
Prospective Data Collection Initiative on Thoracic MalignanciesNCT06996249 · 2025-08-15
RECRUITING
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.NCT06046131 · 2023-02-28
RECRUITING
PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15
RECRUITING
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for CancerNCT05574647 · 2022-11-02
RECRUITING
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerNCT02133196 · 2014-10-23
RECRUITING
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNCT07574541 · 2026-10-12
NOT_YET_RECRUITING
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsNCT05241873 · 2022-03-04
TERMINATED
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in ChinaNCT05337163 · 2022-02-25
COMPLETED
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408 · 2022-01-13
TERMINATED
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29
TERMINATED
The Registry of Oncology Outcomes Associated With Testing and TreatmentNCT04028479 · 2021-05-05
COMPLETED
CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsNCT04660929 · 2021-02-02
UNKNOWN
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerNCT04644770 · 2020-11-12
ACTIVE_NOT_RECRUITING
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective StudyNCT04401059 · 2020-11-09
UNKNOWN
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04222972 · 2020-07-24
TERMINATED
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentNCT04263090 · 2020-06-29
COMPLETED
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLCNCT03636685 · 2018-08-15
UNKNOWN
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.NCT03695835 · 2018-04-11
COMPLETED
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerNCT03215810 · 2017-10-11
COMPLETED
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385 · 2017-03-17
COMPLETED
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung CancerNCT02410603 · 2016-12-01
COMPLETED
cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia ChinaNCT02980536 · 2016-11-01
UNKNOWN
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT02875340 · 2016-10-01
COMPLETED
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsNCT02926768 · 2016-09-01
COMPLETED
HS-PCI in Locally Advanced Adenocarcinoma of the LungNCT02341170 · 2016-01-01
WITHDRAWN
Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of LungNCT02498860 · 2015-09-01
COMPLETED
Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast CancerNCT02404506 · 2015-08-17
TERMINATED
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerNCT02664935 · 2015-05-13
COMPLETED
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCNCT02387216 · 2015-02-01
TERMINATED
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaNCT02125240 · 2014-09-01
UNKNOWN
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ SystemNCT02370303 · 2014-08-01
COMPLETED
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCNCT02194556 · 2014-07-01
UNKNOWN
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyNCT02151149 · 2014-06-09
COMPLETED
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung CancerNCT02183870 · 2014-05-01
COMPLETED
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaNCT02103257 · 2014-03-01
UNKNOWN
Treatment of Multifocal Lung AdenocarcinomaNCT01946100 · 2013-11-06
TERMINATED
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLCNCT01761240 · 2013-06-19
COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine TestingNCT01730118 · 2013-03-04
COMPLETED
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaNCT01665417 · 2012-08-01
UNKNOWN
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone MetastasesNCT01640847 · 2012-07-01
WITHDRAWN

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.